|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0115 AUD | 0.00% |
|
-4.17% | -23.33% |
| 28/05 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 27/05 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 6.16M 4.28M 3.75M 3.46M 3.19M 6.06M 409M 41.3M 16.22M 201M 16.09M 15.74M 692M | P/E 2024 |
-3.44x | P/E 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 8.93M 6.21M 5.43M 5.01M 4.63M 8.78M 592M 59.88M 23.52M 292M 23.32M 22.82M 1B | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/05/22 | Acrux : Application for quotation of securities - ACR | PU |
| 14/04/22 | Acrux : Application for quotation of securities - ACR | PU |
| 16/03/22 | Acrux : Application for quotation of securities - ACR | PU |
| 25/02/22 | Acrux : Updated Board Charter | PU |
| 25/02/22 | Acrux : Application for quotation of securities - ACR | PU |
| 1 week | -4.17% | ||
| Current month | -4.17% | ||
| 1 month | -28.12% | ||
| 3 months | +4.55% | ||
| 6 months | -23.33% | ||
| Current year | -23.33% |
| 1 week | 0.01 | 0.01 | |
| 1 month | 0.01 | 0.02 | |
| Current year | 0.01 | 0.02 | |
| 1 year | 0.01 | 0.02 | |
| 3 years | 0.01 | 0.1 | |
| 5 years | 0.01 | 0.14 | |
| 10 years | 0.01 | 0.84 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 01/06/2025 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21/06/2021 |
| Chief Tech/Sci/R&D Officer | - | 15/02/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ross Dobinson
CHM | Chairman | 74 | 01/01/2006 |
Timothy Oldham
BRD | Director/Board Member | - | 01/10/2013 |
Geoff Brooke
BRD | Director/Board Member | 70 | 01/06/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | -4.17% | -32.35% | -76.04% | 4.11M | ||
| -0.17% | +1.61% | +16.42% | +85.22% | 48.69B | ||
| +1.04% | -1.02% | +69.47% | +115.88% | 36.38B | ||
| -0.13% | -1.29% | -2.60% | +41.58% | 12.19B | ||
| -0.71% | +0.89% | +18.28% | +97.87% | 12.04B | ||
| -0.76% | +0.38% | +33.16% | +123.08% | 9.04B | ||
| -0.86% | +0.37% | +52.61% | -3.54% | 7.06B | ||
| +0.75% | -0.82% | +17.49% | +44.79% | 7.09B | ||
| +0.69% | +3.25% | +19.90% | +243.91% | 6.75B | ||
| +5.45% | -7.36% | -17.93% | +13.17% | 6.1B | ||
| Average | +0.53% | -1.53% | +17.45% | +68.59% | 14.54B | |
| Weighted average by Cap. | +0.34% | +0.09% | +29.83% | +90.69% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.09M 3.54M 3.1M 2.86M 2.64M 5.01M 338M 34.14M 13.41M 166M 13.3M 13.01M 572M | 1.19M 828K 724K 668K 617K 1.17M 78.94M 7.98M 3.13M 38.89M 3.11M 3.04M 134M |
| Net income | -5.8M -4.03M -3.53M -3.25M -3.01M -5.7M -385M -38.89M -15.27M -190M -15.15M -14.82M -652M | -5.94M -4.14M -3.62M -3.34M -3.08M -5.85M -394M -39.86M -15.65M -194M -15.53M -15.19M -668M |
| Net Debt | 759K 528K 462K 426K 393K 746K 50.35M 5.09M 2M 24.8M 1.98M 1.94M 85.27M | 2.77M 1.93M 1.69M 1.56M 1.44M 2.73M 184M 18.59M 7.3M 90.59M 7.24M 7.08M 311M |
Employees
43
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/07/26 | $0.0115 | 0.00% | 290,683 |
| 07/07/26 | $0.0115 | -4.17% | 81,450 |
| 06/07/26 | $0.0120 | 0.00% | 416,666 |
| 03/07/26 | $0.0120 | 0.00% | 540,342 |
| 02/07/26 | $0.0120 | -7.69% | 3,018,264 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
Select your edition
All financial news and data tailored to specific country editions
















